As discussed in our previous update, Crunchfish has now settled on a path forward for the company's ...
Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation so...
Redeye provides some thoughts on and background to the SOLARIO study, which will be presented next w...
Redeye endorses that the FDA has provided positive guidance regarding generic substitutability for I...
Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2...
Redeye positively reviews the Thermo Fisher deal’s potential and the company’s US sales outlook.
Continued sales ramp-up, 32% sales growth q-o-q (ABGSCe +18%) Positive EBIT in FY'24/'25e, ests.
Mangold uppdaterar sin syn på mobiloperatören My Beat efter det första kvartalet.
Redeye does not believe the underlying value of Hexatronic is 10% less due to Larsson Lyon leaving.
Redeye comments on EveryMatrix’s cash offer to acquire Fantasma Games at a price of SEK59 per share,...
Medisol, a European e-commerce specialist,... ...becomes Safe Life's 27th acquisition.
The 15th MSA agreement suggests that Biovica has secured well over 20 MSA-based projects.
Redeye provides a brief comment on Nordisk Games' divestment of approximately 6.
Redeye provides a brief comment on WntResearch’s initial phase 2 data.
Clean Motion AB (”Clean Motion” eller ”Bolaget”) utvecklar och erbjuder hållbara transportlösningar ...
Redeye briefly comments on the recent management change in Integrum.
Redeye comments on Maximum Entertainment following the demand from CEO, Christina Seelye, and COO, T...
Redeye comments on the news about the company’s lower-than-expected number of patients who have achi...
CEO Jean Marie Mognetti participated in ABGSC Fireside Chat Focus on strategy, positioning and oppor...
Mangold återupptar bevakning på cleantech-bolaget Cortus Energy (Cortus).
